A Health Department-commissioned Study Shows Growing Reliance on Cannabis
The health department cannabis study reveals a growing reliance on cannabis for psychiatric conditions. However, limited methodology details restrict clinical analysis. Clinicians await full study data to assess its relevance.
Talking to Teens About Cannabis: Harm Reduction and Clinical Guidance
Adolescent cannabis use harm reduction is critical as legalization expands and exposure patterns shift. Clinicians must understand current evidence on developmental risks to guide teens effectively. Harm reduction approaches focus on delaying use and…
Major Study Links Teen Cannabis Use to Delayed Thinking and Memory Skills
This major study highlights teen cannabis delayed memory effects on adolescent cognitive function. The research shows significant associations between cannabis use and delayed thinking skills. These findings provide critical insights for clinicians…
Trump Signs Order to Fast-Track Psychedelic Research | Euronews – CED Clinic
The focus on psychedelic research acceleration aims to speed up evidence generation for psychiatric conditions. This policy shift may influence FDA approval timelines and clinical trial accessibility. It highlights emerging developments in psychedelic…
Trump Signs Order to Accelerate Psychedelic Drug Research
The focus on psychedelic drug research acceleration is reshaping clinical trial timelines and regulatory pathways. This policy change aims to speed up access to evidence-based psychedelic therapies. Safety protocols and clinical standards remain…
Cannabis and Mental Health: Why the Evidence Looks So Contradictory—and What Actually Matters
Clinicians often face cannabis mental health contradictions in research findings. These contradictions arise from varying THC and CBD effects and individual patient factors. Understanding these contradictions is key for evidence-based clinical decisions.
President Trump Signs Executive Order Encouraging Psychedelic Research
The psychedelic executive order research marks a significant shift in federal policy encouraging clinical trials on psychedelic drugs. This change aims to reduce regulatory barriers and accelerate research on treatment-resistant psychiatric conditions.…
Understanding Cannabis Use Disorder – Addiction Policy Forum
Cannabis use disorder clinical relevance is critical as it affects about 9% of users but remains underdiagnosed. This condition involves withdrawal symptoms and functional impairment. Effective screening and treatment approaches are essential for better…
Trump Accelerates Psychedelic Drug Research to Aid Veterans
Federal policy changes are accelerating psychedelic drug research veterans to improve treatment timelines. This focus on veterans aims to bring MDMA and psilocybin therapies closer to clinical use. The research targets treatment-resistant PTSD and…
Trump Signs Order To Accelerate Legal Access To Psychedelic Therapies For Mental Health
The recent executive order aims to accelerate psychedelic-assisted therapies mental health access, potentially transforming treatment for resistant depression and PTSD. This policy shift could open new pathways for patients who have not responded to…